List view / Grid view
12 December 2013 | By AstraZeneca
Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents...
11 December 2013 | By KDM Communications
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum...
11 December 2013 | By GlaxoSmithKline
Manufacturing sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new state-of-the-art equipment...
10 December 2013 | By Teva
Amir Elstein to succeed Professor Moshe Many...
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
10 December 2013 | By Merck
The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months...
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
10 December 2013 | By Daiichi Sankyo Company
This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
9 December 2013 | By Johnson & Johnson
Sub-Saharan African Ministries of Health invited to submit expression of interest to participate in new effort donation program to be part of broader initiative to raise awareness and action...
9 December 2013 | By Novartis
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials...
9 December 2013 | By AstraZeneca
The donation of the facility and its equipment will ensure that the laboratory continues to serve scientific and research purposes...
8 December 2013 | By Gilead Sciences
In this study, single-agent treatment with idelalisib achieved an overall response rate of 57 percent with a median duration of response of 12.5 months...
6 December 2013 | By Novartis
LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma...
6 December 2013 | By AstraZeneca
Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age...
5 December 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced the formation of the Oncology Clinical and Translational Consortium...
